Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:MBIO NASDAQ:NCNA OTCMKTS:NWBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AMBIOMustang Bio$0.66-5.2%$0.81$0.53▼$7.00$5.27M2.1140,189 shs40,958 shsNCNANuCana$1.97-6.6%$1.94$1.33▼$40.00$8.78M2.1726,124 shs111,506 shsNWBONorthwest Biotherapeutics$0.26+10.2%$0.21$0.19▼$0.37$383.03M-0.743.75 million shs7.32 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%MBIOMustang Bio-5.17%-12.51%-5.71%-22.73%-43.35%NCNANuCana-6.64%-12.44%0.00%-11.66%-76.55%NWBONorthwest Biotherapeutics+10.21%+28.85%+28.40%+2.51%-7.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AMBIOMustang Bio$0.66-5.2%$0.81$0.53▼$7.00$5.27M2.1140,189 shs40,958 shsNCNANuCana$1.97-6.6%$1.94$1.33▼$40.00$8.78M2.1726,124 shs111,506 shsNWBONorthwest Biotherapeutics$0.26+10.2%$0.21$0.19▼$0.37$383.03M-0.743.75 million shs7.32 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%MBIOMustang Bio-5.17%-12.51%-5.71%-22.73%-43.35%NCNANuCana-6.64%-12.44%0.00%-11.66%-76.55%NWBONorthwest Biotherapeutics+10.21%+28.85%+28.40%+2.51%-7.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/AMBIOMustang Bio 1.00SellN/AN/ANCNANuCana 1.00SellN/AN/ANWBONorthwest Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWBO, ARAV, NCNA, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026MBIOMustang Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAraviveN/AN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/A$1.31 per shareN/ANCNANuCanaN/AN/AN/AN/A$7.71 per shareN/ANWBONorthwest Biotherapeutics$1.38M305.91N/AN/A($0.04) per share-6.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAraviveN/A-$0.90N/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio-$1.92M-$0.39N/AN/AN/AN/A-35.38%-16.36%N/ANCNANuCana-$38.71M-$127.73N/AN/AN/AN/A-189.94%-130.93%5/14/2026 (Estimated)NWBONorthwest Biotherapeutics-$60.16M-$18.24N/AN/AN/A-4,365.89%N/A-142.44%5/15/2026 (Estimated)Latest NWBO, ARAV, NCNA, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026N/ANCNANuCana-$2.6440N/AN/AN/AN/AN/A5/5/2026Q1 2026MBIOMustang Bio-$140.00-$0.14+$139.86-$0.14N/AN/A3/19/2026Q4 2025MBIOMustang BioN/A-$0.08N/A-$0.0780N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/AMBIOMustang BioN/A2.122.12NCNANuCanaN/A5.605.60NWBONorthwest BiotherapeuticsN/A0.060.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%MBIOMustang Bio9.95%NCNANuCana44.00%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%MBIOMustang Bio4.00%NCNANuCana31.20%NWBONorthwest Biotherapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataMBIOMustang Bio1007.58 million7.27 millionNot OptionableNCNANuCana304.16 million2.86 millionNot OptionableNWBONorthwest Biotherapeutics201.64 billion1.60 billionNot OptionableNWBO, ARAV, NCNA, and MBIO HeadlinesRecent News About These CompaniesNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average - Here's WhyMay 6, 2026 | marketbeat.comNorthwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine PlatformApril 30, 2026 | prnewswire.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - What's Next?April 28, 2026 | marketbeat.comNorthwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis ClinicApril 21, 2026 | prnewswire.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Passes Below 200-Day Moving Average - What's Next?April 18, 2026 | marketbeat.comNorthwest Biotherapeutics expands authorized common stock capacityJanuary 3, 2026 | msn.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK ...November 22, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK FacilityNovember 20, 2025 | prnewswire.comNorthwest Biotherapeutics Secures $5.5M Loan AgreementOctober 31, 2025 | tipranks.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has ClosedOctober 24, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has ClosedOctober 24, 2025 | prnewswire.comNorthwest Biotherapeutics Inc.October 13, 2025 | barrons.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.August 27, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.August 27, 2025 | prnewswire.comNorthwest Biotherapeutics announces passing of general counsel Les GoldmanAugust 19, 2025 | msn.comNorthwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanAugust 18, 2025 | prnewswire.comNWBO - Northwest Biotherapeutics Inc News - MorningstarJuly 11, 2025 | morningstar.comMNorthwest Biotherapeutics, Inc. (NWBO) - Yahoo FinanceJune 29, 2025 | uk.finance.yahoo.comNWBO Northwest Biotherapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 13, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsJune 11, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, ARAV, NCNA, and MBIO Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 05/8/2026Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Mustang Bio NASDAQ:MBIO$0.66 -0.04 (-5.17%) As of 05/11/2026 04:00 PM EasternMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.NuCana NASDAQ:NCNA$1.97 -0.14 (-6.64%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.42%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Northwest Biotherapeutics OTCMKTS:NWBO$0.26 +0.02 (+10.21%) As of 05/11/2026 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
